JP2023537229A5 - - Google Patents

Info

Publication number
JP2023537229A5
JP2023537229A5 JP2023503508A JP2023503508A JP2023537229A5 JP 2023537229 A5 JP2023537229 A5 JP 2023537229A5 JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023537229 A5 JP2023537229 A5 JP 2023537229A5
Authority
JP
Japan
Prior art keywords
patient
enhancement
pharmaceutical composition
innate immunity
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537229A (ja
Filing date
Publication date
Priority claimed from PCT/IN2021/050325 external-priority patent/WO2021199078A2/en
Application filed filed Critical
Priority claimed from PCT/IN2021/050699 external-priority patent/WO2022018754A1/en
Publication of JP2023537229A publication Critical patent/JP2023537229A/ja
Publication of JP2023537229A5 publication Critical patent/JP2023537229A5/ja
Pending legal-status Critical Current

Links

JP2023503508A 2020-07-18 2021-07-19 SARS-CoV-2タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびCOVID-19を処置するための製剤 Pending JP2023537229A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN202021030633 2020-07-18
IN202021030633 2020-07-18
IN202021054151 2020-12-12
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.
INPCT/IN2021/050325 2021-03-30
PCT/IN2021/050699 WO2022018754A1 (en) 2020-07-18 2021-07-19 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (2)

Publication Number Publication Date
JP2023537229A JP2023537229A (ja) 2023-08-31
JP2023537229A5 true JP2023537229A5 (cg-RX-API-DMAC7.html) 2024-07-26

Family

ID=79728594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503508A Pending JP2023537229A (ja) 2020-07-18 2021-07-19 SARS-CoV-2タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびCOVID-19を処置するための製剤

Country Status (7)

Country Link
US (1) US20240024337A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181917A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023537229A (cg-RX-API-DMAC7.html)
AU (1) AU2021313476A1 (cg-RX-API-DMAC7.html)
CA (2) CA3179022A1 (cg-RX-API-DMAC7.html)
IL (1) IL300014A (cg-RX-API-DMAC7.html)
WO (1) WO2022018754A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115968375A (zh) * 2020-03-29 2023-04-14 阿克西拉制药公司 SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂
AU2022204290A1 (en) * 2020-12-12 2023-07-27 Akseera Pharma Corp. Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
IL316127A (en) * 2022-04-02 2024-12-01 Akseera Pharma Corp Enhancement of antiviral and anticancer therapies by combinations of poly(I:C) and cannabidiol.
WO2023195029A2 (en) * 2022-04-07 2023-10-12 Akseera Pharma Corp. A method of use for cannabidiol in the prevention and treatment of interferon-responsive conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010226604A1 (en) * 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
CN115968375A (zh) * 2020-03-29 2023-04-14 阿克西拉制药公司 SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂
WO2021209998A1 (en) * 2020-04-14 2021-10-21 Molad Ami Composition for the treatment of respiratory symptoms and methods thereof
AU2020447636A1 (en) * 2020-05-11 2022-12-08 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
WO2021231810A1 (en) * 2020-05-14 2021-11-18 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Similar Documents

Publication Publication Date Title
Okyay et al. Another epidemic in the shadow of Covid 19 pandemic: a review of monkeypox
JP2023528561A5 (cg-RX-API-DMAC7.html)
JP2011511754A5 (cg-RX-API-DMAC7.html)
Berry Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System.
LT5079B (lt) Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai
Wang et al. Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation
Gao et al. Induction of SOCS expression by EV71 infection promotes EV71 replication
JP2010530423A (ja) 免疫活性化剤を用いたウイルス感染の早期介入
CN116251114A (zh) 龙胆苦苷在制备防控病毒或细菌感染的药物中的应用
JP2003528925A5 (cg-RX-API-DMAC7.html)
JP2023518390A (ja) ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物
Denholm et al. SARS-CoV-2-induced senescence as a potential therapeutic target
CN106176700A (zh) 氯硝柳胺在制备抗致瘤疱疹病毒药物中的应用
AU2023248776A1 (en) A method of use for cannabidiol in the prevention and treatment of interferon-responsive conditions
Stebbing et al. Kaposi's sarcoma—an update
CN102697832B (zh) 金银花水提物和let-7a microRNA在制备预防及治疗登革病毒和登革热药物与保健品中的应用
Yuliia MEDICAL SCIENCES
Alhiti Nanosilver plus Bacteriophages Cured COVID
Haq TYPE I INTERFERON: ANTIVIRAL IS NEED OF THE TIME FOR COVID-19
Li et al. The effect of Gankang Suppository on duck hepatitis B virus, serum biochemistry and liver histology in ducklings
US20230277650A1 (en) Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv)
Solanki et al. Drug Development
Abbaszadeh et al. Bacteriophages: A possible choice for treatment of viral respiratory infections and COVID-19
Brandão et al. Prolonged survival of rabid mice after treatment with Poly-ICLC Hiltonol®
Mtewa et al. SARS-CoV-2 vaccine development